Edgar Filing: Anthera Pharmaceuticals Inc - Form 4

Anthera Ph Form 4	armaceuticals Inc								
May 22, 20	15								
FORM	/ / /		CECU			CHANGE			PPROVAL
Washington, D.C. 20549									3235-0287
Check this box if no longer subject to STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF									January 31, 2005
subject Section Form 4	NGES IN SECUR		Estimated burden hou response	average urs per					
Form 5 obligati may co <i>See</i> Inst 1(b).	ons Section 170	(a) of the l	Public U	Jtility Hol	ding Cor		nge Act of 1934, of 1935 or Secti 940		
(Print or Type	Responses)								
1. Name and Address of Reporting Person <u>*</u> Sager Philip			2. Issuer Name and Ticker or Trading Symbol			5. Relationship of Reporting Person(s) to Issuer			
			Anthera Pharmaceuticals Inc [ANTH]				(Check all applicable)		
(Last) (First) (Middle)			3. Date of Earliest Transaction (Month/Day/Year)			Director 10% Owner Officer (give title Other (specify below) below)			
25801 INE SUITE B	OUSTRIAL BLVE).,	05/21/2	2015			below)	below)	
			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person			
HAYWAR	RD, CA 94545						Form filed by Person	More than One R	eporting
(City)	(State)	(Zip)	Tat	ole I - Non-I	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)2A. Deeme Execution I any (Month/Day/Year)		Date, if Transaction		Disposed	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code V	Amount	(D) Price	(Instr. 3 and 4)		
Reminder: Re	eport on a separate line	e for each cl	ass of sec	urities benef	ficially ow	ned directly o	or indirectly.		
					inforn requi	nation cont red to respo ays a curre	spond to the colle tained in this forn ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)
	Tab					posed of, or convertible :	Beneficially Owner securities)	d	

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	8
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transaction	Derivative	Expiration Date	Underlying Securities	D

Edgar Filing: Anthera Pharmaceuticals Inc - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		(Month/Day/Year)		(Instr. 3 and 4)		S (1
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 4.75	05/21/2015		А	28,846		<u>(1)</u>	05/21/2025	Common Stock	28,846 (1)	

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Sager Philip							
25801 INDUSTRIAL BLVD., SUITE B							
HAYWARD, CA 94545							

Signatures

/s/ May Liu, by power of 05/22/2015 attorney

**Signature of Reporting Person

Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v). *
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The stock option vests and becomes exercisable in 12 equal monthly installments from the vesting commencement date of May 21, 2015. (1) This stock option is fully exercisable on May 21, 2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.